ArticleFrontiers in psychiatry2026
Weight mitigation and tolerability of adjunctive topiramate in acute pediatric psychiatry: a retrospective real-world analysis.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objective: Psychotropic medications are often associated with significant and rapid weight gain in pediatric populations, especially second-generation antipsychotics and mood stabilizers. This was a retrospective study assessing weight gain, and tolerability of adjunctive topiramate in hospitalized child and adolescent psychiatric patients. Methods: A total of 285 inpatients were included in the study: an intervention group (n = 45) receiving adjunctive topiramate and a control group (n = 240) receiving standard care. Net weight, polypharmacy burden (chlorpromazine [CPZ] equivalent doses and other mood stabilizers) and psychiatric recovery (Global Assessment of Functioning [GAF] and Clinical Global Impression-Severity [CGI-S] scores) were measured. Hierarchical ANCOVA models were employed to disentangle the independent metabolic effects of topiramate from the confounding effects of polypharmacy. Results: The mean weight gain in the control group was significantly greater than in the topiramate group (3.3 kg vs -0.1 kg, p < 0.001). This protective metabolic effect persisted with high statistical significance even after controlling for the concurrent CPZ equivalent dose (3.1 kg advantage). Clinical recovery, measured by equivalent improvement in GAF scores and reduction in CGI-S scores, was similar for both groups. Conclusions: Adjunctive topiramate is a highly effective and safe metabolic shield in acute pediatric inpatient settings. It reduces the risk of psychotropic weight gain and can substantially reduce the need for obesogenic polypharmacy, without impeding the course of psychiatric recovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.